Objective: Evaluate the RIBA™ HSV 1/2 SU for HSV Ab typing in culture documented HSV-1 and HSV-2 cases, with the CDC HSV and CMV Evaluation Panel (CDC-EP), and in selected clinical populations. Methods: Sera from 27 HSV-1 and 339 HSV-2 culture positive subjects were tested by RIBA™ SIA. A second study compared RIBA™ SIA against the CDC-EP, which consists of 100 well characterized sera from healthy donors. Results from the study were compared to those from the CDC-EIA and the CDC-gG blot for Ab to HSV-1 and HSV-2. In addition, 858 specimens from STD clinic clients, children, pregnant women, and transplant patients were tested by the RIBA™ SIA and a commercial HSV EIA with Ab typing confirmed by Western Blot (UW). Results: Against culture, sensitivity of the RIBA™ SIA was 93% for HSV-1 and 99% for HSV-2. In the second study with the CDC-EP, RIBA™ SIA showed 100% sensitivity and specificity vs CDC-EIA, with a 97% typing agreement with the CDC-gG blot for HSV-1 and HSV-2. In the 858 sera from different patient populations, sensitivity and specificity of the RIBA™ SIA vs EIA were 95% and 99% respectively with PPVs of 97% for HSV-1 and HSV-2 vs Western Blot. Conclusion: RIBA™ SIA provides accurate HSV Ab typing results compared to culture and Western Blot. This accurate, easy to use, type specific serological test may have wide clinical applicability.
|Original language||English (US)|
|Number of pages||1|
|Journal||Clinical Infectious Diseases|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases